Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/32131
Title: Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
Authors: 
Mesh: 
Issue Date: 2017
Citation: J. Natl. Cancer Inst..2017 09;(109)9:
Abstract: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC) is limited by adaptive activation of cell survival signals. We hypothesized that both signal transducer and activator of transcription 3 (STAT3) and Src-YES-associated protein 1 (YAP1) signaling are dually activated during EGFR TKI treatment to limit therapeutic response.
PMID: 28376152
URI: https://hdl.handle.net/20.500.12530/32131
Rights: openAccess
Appears in Collections:Hospitales > H. U. Puerta de Hierro Majadahonda > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. La Princesa > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Puerta de Hierro-Segovia de Arana > Artículos

Files in This Item:
File Description SizeFormat 
PMC5409000.pdf1.46 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.